Search results
Results From The WOW.Com Content Network
The combination milbemycin oxime/lufenuron (trade names Sentinel Flavor Tabs, by Novartis Animal Health, and Program plus) is a parasite control drug in which the active ingredient, milbemycin oxime, eliminates worms, while a second active ingredient, lufenuron, arrests the development of eggs and larvae, preventing them from maturing and ...
9. Beagle. tetiana_u - Shutterstock. If you're looking for a dog full of personality, then a beagle might be the one for you and your family. This is a super playful breed with a ton of energy ...
Pimobendan ( INN, or pimobendane ), sold under the brand name Vetmedin among others, is a veterinary medication. It is a calcium sensitizer and a selective inhibitor of phosphodiesterase 3 (PDE3) with positive inotropic and vasodilator effects. Pimobendan is used in the management of heart failure in dogs, most commonly caused by myxomatous ...
Acepromazine. Acepromazine, acetopromazine, or acetylpromazine (commonly known as ACP, Ace, or by the trade names Atravet or Acezine 2, number depending on mg/ml dose) is a phenothiazine derivative antipsychotic drug. It was used in humans during the 1950s as an antipsychotic, [ 4] but is now almost exclusively used on animals as a sedative and ...
For heartworm prevention, the typical dose is relatively low, at 0.0015 – 0.003 mg per pound of body weight, administered orally once a month. For the treatment of mange, doses can be higher and ...
You can find instant answers on our AOL Mail help page. Should you need additional assistance we have experts available around the clock at 800-730-2563.
August 8, 2024 at 10:55 AM. By Mariam Sunny. (Reuters) -The U.S. Food and Drug Administration has approved Citius Pharmaceuticals' therapy for patients with a form of blood cancer who have ...
Canine histiocytic diseases. Histiocytic diseases in dogs are a group of diseases in dogs which may involve the skin, and which can be difficult to differentiate from granulomatous, reactive inflammatory or lymphoproliferative diseases. The clinical presentation and behaviour as well as response to therapy vary greatly among the syndromes.